Stock Scorer

Clover Health Investments, Corp. /DE (CLOV)

Clover Health Investments, Corp. /DE reported revenue of 743.2M USD for the quarter ending 30 June 2026, up 55.6% from 477.6M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 743.2M +55.6%
Gross Profit Q3 '24 · ending 30 September 2024 81.2M +15.6%
Operating Income Q2 '26 · ending 30 June 2026 28M —
Net Income Q2 '26 · ending 30 June 2026 28M —
Operating Cash Flow Q2 '26 · ending 30 June 2026 25.2M +365.8%
Free Cash Flow Q2 '26 · ending 30 June 2026 24.5M +406.4%
Shares Outstanding Q2 '26 · ending 30 June 2026 545.4M +9.7%
EPS Q4 '23 · ending 31 December 2023 -0.44 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 1.9B-85.5M-85.5M-69M
20242024-12-31 1.4B-45.7M-43M33.3M
20232023-12-31 1.3B-205.3M-213.4M-145.2M
20222022-12-31 1.1B-286.7M-339.6M-208.4M
20212021-12-31 1.5B-637M-587.8M-283M
20202020-12-31 672.9M-92.7M-136.4M-119.2M
20192019-12-31 462.3M-183.2M-363.7M-159.9M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-30743.2M
Q1 '262026-03-31749.2M
Q4 '252025-12-31487.7M
Q3 '252025-09-30496.6M
Q2 '252025-06-30477.6M
Q1 '252025-03-31462.3M
Q4 '242024-12-31337M
Q3 '242024-09-30331M
Q2 '242024-06-30356.3M
Q1 '242024-03-31346.9M
Q4 '232023-12-31312.4M
Q3 '232023-09-30306M
Q2 '232023-06-30320.1M
Q1 '232023-03-31322M
Q3 '222022-09-30856.8M
Q2 '222022-06-30846.7M
Q1 '222022-03-31874.4M
Q4 '212021-12-31432M
Q3 '212021-09-30427.2M
Q2 '212021-06-30412.5M

Gross Profit Quarterly

PeriodEndingGross Profit
Q3 '242024-09-3081.2M
Q2 '242024-06-30107.9M
Q1 '242024-03-3181.8M
Q4 '232023-12-3164M
Q3 '232023-09-3070.2M
Q2 '232023-06-3075.9M
Q1 '232023-03-3147.2M
Q4 '222022-12-315.1M
Q3 '222022-09-3017M
Q2 '222022-06-30-12.1M
Q1 '222022-03-3112.7M
Q4 '212021-12-31-9.9M
Q3 '212021-09-30-9.2M
Q2 '212021-06-30-46M
Q1 '212021-03-31-14.1M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-3028M
Q1 '262026-03-3127.3M
Q4 '252025-12-31-49.3M
Q3 '252025-09-30-24.4M
Q2 '252025-06-30-10.6M
Q1 '252025-03-31-1.3M
Q4 '242024-12-31-21.4M
Q3 '242024-09-30-8.8M
Q2 '242024-06-307.2M
Q1 '242024-03-31-22.7M
Q4 '232023-12-31-63.1M
Q3 '232023-09-30-33.6M
Q2 '232023-06-30-28.9M
Q1 '232023-03-31-79.7M
Q4 '222022-12-31-22.4M
Q3 '222022-09-30-74.1M
Q2 '222022-06-30-102.7M
Q1 '222022-03-31-87.5M
Q4 '212021-12-31-186.8M
Q3 '212021-09-30-149.3M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-3028M
Q1 '262026-03-3127.3M
Q4 '252025-12-31-49.3M
Q3 '252025-09-30-24.4M
Q2 '252025-06-30-10.6M
Q1 '252025-03-31-1.3M
Q4 '242024-12-31-22.1M
Q3 '242024-09-30-9.2M
Q2 '242024-06-307.4M
Q1 '242024-03-31-19.2M
Q4 '232023-12-31-70.5M
Q3 '232023-09-30-41.5M
Q2 '232023-06-30-28.8M
Q1 '232023-03-31-72.6M
Q4 '222022-12-31-84.2M
Q3 '222022-09-30-75.5M
Q2 '222022-06-30-104.4M
Q1 '222022-03-31-75.5M
Q4 '212021-12-31-187.2M
Q3 '212021-09-30-34.5M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-3025.2M
Q1 '262026-03-31107.9M
Q4 '252025-12-31-68.2M
Q3 '252025-09-3012.1M
Q2 '252025-06-305.4M
Q1 '252025-03-31-16.3M
Q3 '242024-09-3050M
Q2 '242024-06-3044.8M
Q1 '242024-03-3125.9M
Q4 '232023-12-31-258.1M
Q3 '232023-09-30-18.8M
Q2 '232023-06-3053.2M
Q1 '232023-03-3179M
Q4 '222022-12-31-209.4M
Q3 '222022-09-30101.7M
Q2 '222022-06-30-39.2M
Q1 '222022-03-31-57M
Q4 '212021-12-31-80.2M
Q3 '212021-09-30-45.1M
Q2 '212021-06-30-64.2M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-3024.5M
Q1 '262026-03-31107M
Q4 '252025-12-31-68.7M
Q3 '252025-09-3011.4M
Q2 '252025-06-304.8M
Q1 '252025-03-31-16.5M
Q3 '242024-09-3049.6M
Q2 '242024-06-3044.4M
Q1 '242024-03-3125.5M
Q3 '232023-09-30-19M
Q2 '232023-06-3052.8M
Q1 '232023-03-3178.8M
Q4 '222022-12-31-213.2M
Q3 '222022-09-30101.4M
Q2 '222022-06-30-39.3M
Q1 '222022-03-31-57.2M
Q4 '212021-12-31-80.4M
Q3 '212021-09-30-45.3M
Q2 '212021-06-30-64.3M
Q1 '212021-03-31-93M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30545.4M
Q1 '262026-03-31532.5M
Q3 '252025-09-30512.7M
Q2 '252025-06-30509M
Q1 '252025-03-31497.1M
Q3 '242024-09-30490.2M
Q2 '242024-06-30495.2M
Q1 '242024-03-31486.4M
Q3 '232023-09-30480.8M
Q2 '232023-06-30479.2M
Q1 '232023-03-31478.8M
Q3 '222022-09-30477.7M
Q2 '222022-06-30476.1M
Q1 '222022-03-31473M
Q3 '212021-09-30414.6M
Q2 '212021-06-30408.2M
Q1 '212021-03-31376.2M
Q3 '202020-09-30248.1M
Q2 '202020-06-30242.6M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q4 '232023-12-31-0.44
Q3 '232023-09-30-0.47
Q2 '232023-06-30-0.54
Q1 '232023-03-31-0.70
Q4 '222022-12-31-0.71
Q3 '222022-09-30-0.98
Q2 '222022-06-30-0.90
Q1 '222022-03-31-1.46
Q4 '212021-12-31-1.43
Q3 '212021-09-30-2.42
Q2 '212021-06-30-2.32
Q1 '212021-03-31-1.53
Q4 '202020-12-31-1.40